Novartis AG Operating Income 2010-2022 | NVS

Novartis AG annual/quarterly operating income history and growth rate from 2010 to 2022. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
  • Novartis AG operating income for the quarter ending March 31, 2022 was $2.852B, a 18.1% increase year-over-year.
  • Novartis AG operating income for the twelve months ending March 31, 2022 was $12.126B, a 23.44% increase year-over-year.
  • Novartis AG annual operating income for 2021 was $11.689B, a 15.14% increase from 2020.
  • Novartis AG annual operating income for 2020 was $10.152B, a 11.73% increase from 2019.
  • Novartis AG annual operating income for 2019 was $9.086B, a 8.13% increase from 2018.
Novartis AG Annual Operating Income
(Millions of US $)
2021 $11,689
2020 $10,152
2019 $9,086
2018 $8,403
2017 $8,629
2016 $8,268
2015 $8,977
2014 $11,089
2013 $10,983
2012 $11,507
2011 $10,780
2010 $11,526
2009 $9,982
Novartis AG Quarterly Operating Income
(Millions of US $)
2022-03-31 $2,852
2021-12-31 $6,500
2021-09-30 $-705
2021-06-30 $3,479
2021-03-31 $2,415
2020-12-31 $6,397
2020-09-30 $-1,341
2020-06-30 $2,352
2020-03-31 $2,744
2019-12-31 $1,823
2019-09-30 $2,358
2019-06-30 $2,663
2019-03-31 $2,242
2018-12-31 $1,362
2018-09-30 $2,239
2018-06-30 $2,431
2018-03-31 $2,371
2017-12-31 $2,070
2017-09-30 $2,357
2017-06-30 $2,280
2017-03-31 $1,922
2016-12-31 $1,455
2016-09-30 $2,269
2016-06-30 $2,093
2016-03-31 $2,451
2015-12-31 $1,677
2015-09-30 $2,234
2015-06-30 $2,281
2015-03-31 $2,785
2014-12-31 $2,351
2014-09-30 $2,739
2014-06-30 $3,184
2014-03-31 $2,815
2013-12-31 $2,496
2013-09-30 $2,558
2013-06-30 $3,033
2013-03-31 $2,896
2012-12-31 $2,715
2012-09-30 $2,948
2012-06-30 $3,108
2012-03-31 $2,736
2011-12-31 $1,099
2011-09-30 $2,951
2011-06-30 $3,322
2011-03-31 $3,408
2010-12-31 $2,467
2010-09-30 $2,587
2010-06-30 $2,961
2010-03-31 $3,511
2009-12-31 $2,637
2009-09-30 $2,634
2009-06-30 $2,364
2009-03-31 $2,347
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $188.691B $52.877B
Novartis has one of the strongest and broadest portfolio of oncology drugs and generics. It continues to build depth in 5 core therapeutic areas Cardio-Renal, Immunology, Neuroscience, Oncology and Hematology, strength in technology platforms - Targeted Protein Degradation, Cell Therapy, Gene Therapy, Radioligand Therapy, and xRNA. Novartis efforts to strengthen its wide and deep oncology portfolio by developing breakthrough treatments. Cosentyx, Entresto, Kesimpta, Zolgensma, Kisqali and Leqvio. In March 2015, Novartis acquired certain oncology products and pipeline compounds from Glaxo. In exchange, it sold its non-influenza Vaccines business to Glaxo. Also, the company has spun off the Alcon business into a separate company. In January 2015, Novartis divested its Animal Health division to Lilly. In July 2015, the company divested its influenza vaccines business to CSL Limited. Novartis has also acquired The Medicines Company, adding Leqvio, to its portfolio. Novartis sold its investment in Roche.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $479.231B 18.43
Eli Lilly (LLY) United States $310.959B 36.69
Pfizer (PFE) United States $291.093B 10.15
AbbVie (ABBV) United States $270.615B 11.86
Merck (MRK) United States $238.745B 13.49
GlaxoSmithKline (GSK) United Kingdom $111.076B 12.97
Novo Nordisk (NVO) Denmark $0.000B 33.60